Objectives: SMART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing study to monitor worldwide antimicrobial resistance trends among aerobic and facultatively anaerobic Gramnegative bacilli (GNB) isolated from intra-abdominal infections. This 2004 report summarizes the most recently completed annual data from SMART.
Introduction
International surveillance programmes have been developed to monitor the emerging global threat of antibiotic-resistant bacteria. The Study for Monitoring Antimicrobial Resistance Trends (SMART), begun in 2002, is the only worldwide surveillance programme specifically designed to monitor longitudinally the in vitro antimicrobial susceptibility of aerobic and facultatively anaerobic Gram-negative bacilli (GNB) isolated exclusively from intra-abdominal sites. Results from SMART in 2003, the first full year of the study, showed that Enterobacteriaceae composed the vast majority of aerobic or facultatively anaerobic GNB isolated from intra-abdominal infections, with Escherichia coli being the most commonly isolated species. 1 Antimicrobial resistance was confirmed to be a worldwide problem, especially in the Asia/ Pacific region. 1 This report summarizes results for 2004, the second full year of the study.
Materials and methods
Eighty-one medical centres from 28 countries in five geographic regions participated in SMART during 2004, including sites in Asia/Pacific [14 centres: China (4), Taiwan (3), Korea (2), Australia (2), New Zealand (2), Philippines (1) (5), France (4), Germany (3), Belgium (2), Italy (2), Estonia (1), Finland (1), Greece (1) ], Latin America [17 centres in Central and South America: Argentina (3), Brazil (3), Chile (2), Mexico (2), Puerto Rico (2), Colombia (1), Ecuador (1), Guatemala (1), Panama (1), Venezuela (1)] and the Middle East/Africa [7 centres: Israel (4) , South Africa (3)].
Collection and antimicrobial susceptibility testing of aerobic and facultatively anaerobic GNB from intra-abdominal infections was performed as previously reported. 1 Reference strains E. coli ATCC 25922, Klebsiella pneumoniae ATCC 700603 and Pseudomonas aeruginosa ATCC 27853 were used as quality control strains for each batch of MIC tests. Phenotypic identification of extended-spectrum b-lactamase (ESBL) production was applied to test E. coli, Klebsiella spp. and Enterobacter spp., and performed using a modification of the CLSI method.
2 If the ceftazidime, ceftriaxone or cefepime MIC was ‡2 mg/L, then the MIC of cefepime was compared with the MIC of cefepime plus clavulanic acid (10 mg). ESBL production was operationally defined as a ‡8-fold decrease in the cefepime MIC when tested in combination with clavulanic acid compared with in the absence of clavulanic acid. E. coli, Klebsiella spp. and Enterobacter spp. confirmed phenotypically to produce ESBLs were designated as resistant to ceftazidime, ceftriaxone and cefepime regardless of whether their MICs were below the CLSI breakpoint for susceptibility.
For comparisons of susceptibility rates, 95% confidence intervals were calculated for the difference using the method of Miettenen and Nurminen. 3 No formal hypothesis-testing was performed. No statistical adjustment was made for computing multiple confidence intervals.
Results and discussion
A total of 6156 aerobic and facultatively anaerobic GNB were isolated from intra-abdominal infections in 5731 patients from the 81 participating study centres in 28 countries worldwide in 2004. Susceptibility results for the most frequently isolated GNB (n ‡ 10 isolates) are presented in (4498/5317) of the Enterobacteriaceae isolates. Among the antimicrobial agents tested, the three carbapenems (ertapenem, imipenem and meropenem) and amikacin were the most consistently active in vitro against the Enterobacteriaceae. Ciprofloxacin and levofloxacin were the least reliably active agents against E. coli overall with the lowest activity seen in Asia/Pacific (64.5% and 66.0% susceptible, respectively) and Latin America (72.1% and 74.3% susceptible, respectively). The low susceptibility rates observed for E. coli to ciprofloxacin and levofloxacin compared with the other agents tested were consistent in all geographic regions worldwide. The least active agents against Klebsiella spp. were ceftriaxone, ceftazidime and cefepime, especially in Latin America (range 70.6-72.4%) and Middle East/Africa (72.6%). The least active agents against Enterobacter spp. were ceftriaxone and ceftazidime, most notably in Asia/Pacific (45.8% and 44.8% susceptible, respectively) and the USA (51.6% and 52.7% susceptible, respectively). Cefepime was more active than ceftriaxone and ceftazidime against Enterobacter spp. overall, but its activity varied by region, ranging from 63.5% susceptible in Asia/Pacific to 88.2% susceptible in Europe. Table 2 . A slight decrease in susceptibility to the extended-spectrum cephalosporins and the quinolones was observed from 2003 to 2004. Whether this observation portends a long-term trend remains to be determined as the SMART study continues to accumulate annual data in subsequent years. Other investigators have noted a decrease in fluoroquinolone susceptibilities among Enterobacteriaceae in recent years. 4 A retrospective cohort study identified fluoroquinolone resistance to be an independent risk factor for mortality in patients with healthcare-acquired E. coli and K. pneumoniae infections, 5 perhaps attributable in part to a delay in the initiation of appropriate antimicrobial therapy in patients with fluoroquinoloneresistant infections.
ESBL production was detected phenotypically in 10% of E. coli, 17% of Klebsiella spp. (18% K. pneumoniae and 15% Klebsiella oxytoca) and 22% of Enterobacter spp. (22% Enterobacter cloacae and 24% Enterobacter aerogenes) worldwide. The prevalence of confirmed ESBL-positive isolates in the USA, Europe, Latin America, Middle East/Africa and Asia/ Pacific among E. coli was 2.8%, 6.4%, 12.0%, 10.0% and 19.6%; among Klebsiella spp. was 5.3%, 8.8%, 27.6%, 27.4% and 22.9%; and among Enterobacter spp. was 25.3%, 11.8%, 31.1%, 17.8% and 36.4%, respectively. When susceptibilities of ESBL and non-ESBL producers were compared, the differences in susceptibility rates for the carbapenems were smaller than the differences in susceptibility rates for the other agents tested (Table 3) . Overall, ESBLs were detected less frequently in organisms isolated <48 h after hospitalization than in organisms isolated ‡48 h after hospitalization among E. coli (6.7% versus 13.2%), Klebsiella spp. (9.0% versus 21.9%) and Enterobacter spp. (15.7% versus 24.8%).
The emergence of ESBL-producing Enterobacteriaceae has made in vitro susceptibility testing more complicated. Although the MIC of some cephalosporins for certain ESBL producers can fall below the traditional CLSI susceptibility breakpoint, these GNB should be considered resistant to cephalosporins (except cephamycins) if an ESBL is confirmed. 6 The current 48. 6 (37.2, 58.9) 27. 1 (18.8, 37.4) 55. 5 (44.5, 65.5) 36. 2 (25.7, 47.2) 32. 7 (22.7, 43.6) E. aerogenes 6 (-9.0, 10.9) 11.7 (-2.1, 20.8) 48. 4 (26.9, 66.2) 24.0 (11. 5, 43.5) 36.0 (20.2, 55.6) 28.3 (9.5, 48.8) 17. 5 (3.0, 37.6) EPM, ertapenem; IPM, imipenem; MEM, meropenem; FOX, cefoxitin; TZP, piperacillin/tazobactam; AMK, amikacin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin.
a The 95% confidence intervals (CI) for the difference calculated as the % susceptible rate for non-ESBL producers minus the % susceptible rate for ESBL producers were determined using the Miettinen-Nurminen method.
CLSI guidelines for screening and confirming ESBL in E. coli, K. pneumoniae and K. oxytoca (and Proteus mirabilis when clinically relevant) may not be appropriate for testing other Enterobacteriaceae such as Enterobacter spp. that possess the inducible chromosomal ampC b-lactamase gene or Klebsiella spp. that possess a plasmid-mediated ampC gene. 6, 7 Since both cefotaxime and ceftazidime are susceptible to hydrolysis by the AmpC enzyme, the presence of an ESBL may not be detected in an organism that also produces a significant amount of AmpC when these two agents are used in combination with clavulanic acid in the ESBL confirmatory test. One proposed modification is to add cefepime as a screening agent, as well as in the confirmatory test in combination with clavulanic acid, since cefepime is relatively resistant to hydrolysis by AmpC. [7] [8] [9] However, our exclusive use of cefepime as the only cephalosporin with clavulanic acid in the confirmatory ESBL test may have potentially resulted in under-reporting of the prevalence of ESBLs, since the activity of individual cephalosporins against certain ESBLproducing organisms may vary.
ESBLs were detected in slightly higher numbers in the 2004 than the 2003 SMART study among E. coli (10% versus 9%), Klebsiella spp. (17% versus 14%) and Enterobacter spp. (22% versus 14%). 1 The high frequency of ESBL isolation observed in some regions in our study is noteworthy (for example, 19.6% of E. coli in Asia/Pacific; 27.6% of Klebsiella spp. in Latin America and 36.4% of Enterobacter spp. in Asia/Pacific) and raises the question of whether extended-spectrum cephalosporins should still be considered among the optimal empirical regimens for intra-abdominal infections in some geographic areas. There were relatively small differences in susceptibility rates for the carbapenems between the ESBL producers and the non-ESBL producers, as compared with the generally much larger differences in susceptibility rates for piperacillin/tazobactam, ciprofloxacin, levofloxacin, tobramycin and amikacin. These data are consistent with previous reports linking resistance to non-blactam agents with the presence of ESBLs. 10 All surveillance studies have their limitations. Although the 2004 SMART study was global, and included 81 study sites (compared with 74 sites in 2003), sites in each geographic region were not uniformly distributed. Consequently, the results from any country or region should be extrapolated cautiously. Only sixty of the 74 study sites from 2003 participated in 2004, confounding direct comparisons between these two years. Since there is an ongoing effort to recruit more study sites in countries that are under-represented or not represented at all, it is anticipated that the study in future years will not only have more centres, but also a more balanced geographic distribution. As data accrue on an annual basis, SMART will be able to provide analyses of longitudinal trends in regional antimicrobial resistance patterns among GNB isolated from intra-abdominal infections.
